NewTimeSpace News: CStone Pharmaceuticals (02616.HK) announced its proposal to repurchase up to 136,450,133 shares from time to time on the open market. The share repurchase plan is expected to be implemented after the ASCO Annual Meeting, fully demonstrating the management and the Board’s firm confidence in the Company’s R&D achievements, commercial progress and long-term business development.
NewTimeSpace News: On May 13, China Carbon Neutral announced that the company has entered into a subscription agreement with three subscribers, proposing to issue a total of approximately 96.59 million new shares at HK$0.80 per share, with net proceeds of around HK$77.27 million.
NewTimeSpace News: May 13, 2026, POU SHENG INT'L(03813.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.05 billion, decreased by 1.09% YoY
NewTimeSpace News: May 13, 2026, YUE YUEN IND(00551.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at USD 1.99 billion, decreased by 2.17% YoY
NewTimeSpace News: May 13, 2026, TCL ELECTRONICS(01070.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at HKD 29.23 billion, increased by 15.28% YoY
NewTimeSpace News: On May 13, GF Securities announced that the Company’s publicly issued 2023 Perpetual Subordinated Bond (Tranche 3) will pay interest on May 15, 2026.
NewTimeSpace News: By the close of trading on May 13, 2026, HANS CNC(03200.HK) saw a gain of 30.91% in its share price, closing at HKD 185. During the session, it reached an intraday high of HKD 189 and touched an intraday low of HKD 138.5.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the Phase I clinical trial of its self-developed HLX48 for injection, an EGFR/c-MET dual-target antibody-drug conjugate (ADC) for advanced/metastatic solid tumors, has been approved by the relevant Human Research Ethics Committee and completed clinical trial notification with Australia’s Therapeutic Goods Administration (TGA). No 同类 bispecific ADC has been approved globally so far.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that its self-developed HLX97, a KAT6A/B small-molecule inhibitor, has completed first patient dosing in China for the Phase I clinical trial in patients with advanced/metastatic solid tumors. The candidate is intended for the treatment of advanced and metastatic solid tumors, and no KAT6A/B small-molecule inhibitor has been approved worldwide to date.
By the close of trading on May 13, 2026, INNOSCIENCE(02577.HK) saw a gain of 19.26% in its share price, closing at HKD 83.6. During the session, it reached an intraday high of HKD 84.85 and touched an intraday low of HKD 68.6.
NewTimeSpace News: On May 12, SINGAPORE INST OF ADV MED announced that it has received the listing and quotation notice from SGX-ST, approving the issuance of up to approximately 493 million rights shares and an equivalent number of free warrants on the basis of two rights shares for every five existing shares held.
NewTimeSpace News: On May 13, NATSTORAGE announced that the delisting of the underlying securities from the Australian Securities Exchange due to a takeover transaction has triggered the issuer’s redemption right. The issuer has notified that it will redeem all outstanding 3.625% exchangeable notes at par on 9 June 2026, with a total redemption amount of approximately A$10.786 million.
NewTimeSpace News: CHINAHONGQIAO(01378.HK) will spend HKD 275.63 million to repurchase 8.27 million shares on May 12, 2026.
NewTimeSpace News: May 13, 2026, NISSIN FOODS(01475.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at HKD 1.12 billion, increased by 4.07% YoY
NewTimeSpace News: Harbour BioMed Holdings Limited (02142.HK) announced that Dr. Ye Xiaoping, Independent Non-executive Director of the Company, received a case filing notice from the CSRC on May 12, 2026. Dr. Ye is placed under investigation on suspicion of information disclosure irregularities related to shareholding changes of Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye is not involved in the Group’s daily management or operations, and the Company’s business operations remain normal.
NewTimeSpace News, May 13, 2026, TRADEGO(08017.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 186.57 million, increased by 43.85% YoY
